Kerri Fitzgerald

Articles by Kerri Fitzgerald

Kerri FitzgeraldSNMMI | June 15, 2022
The approach may help inform clinical decision-making early in treatment.
Read More
Kerri FitzgeraldSNMMI | June 14, 2022
The authors of the study won the 2022 SNMMI Abstract of the Year Award.
Kerri FitzgeraldSNMMI | June 14, 2022
The novel artificial intelligence can produce high-quality PET/CT images while decreasing radiation exposure to ...
Kerri FitzgeraldOncology | February 16, 2021
A study published in the European Journal of Haematology found that a diagnosis of primary myelofibrosis (MF) or ...
Kerri FitzgeraldOsteoarthritis | February 11, 2021
In patients with an unsatisfactory response to first knee replacement, the best predictor of achieving a satisfactory ...
Kerri FitzgeraldASH Annual Meeting 2020 | December 17, 2020
Sickle cell disease (SCD) shortens life expectancy and leads to morbidity. Recent advancements in allogeneic ...
Kerri FitzgeraldASH Annual Meeting 2020 | December 17, 2020
Alpha-globin mutations are common, and the number and type of mutated alleles will determine the severity of subsequent ...
Kerri FitzgeraldASH Annual Meeting 2020 | December 17, 2020
At the all-virtual 62nd ASH Annual Meeting & Exposition, researchers presented data from an ongoing phase I/II trial ...
Kerri FitzgeraldOsteoporosis | December 14, 2020
A study published as part of the American College of Rheumatology Annual Meeting compared denosumab versus alendronate ...
Kerri FitzgeraldOncology | December 1, 2020
Ankit Kansagra, MD, an assistant professor in the Department of Internal Medicine at UT Southwestern Medical Center ...
Kerri FitzgeraldCOVID-19 | November 20, 2020
A study published in Blood identified the following factors as predictive of worse outcomes for patients with multiple ...
Kerri FitzgeraldOsteoporosis | November 17, 2020
Romosozumab produces “substantial” bone mineral density (BMD) gains at the total hip and lumbar spine within one ...
Kerri FitzgeraldOncology | September 16, 2020
A study presented at the 2020 Society of Hematologic Oncology Annual Meeting found that the addition of ixazomib to ...
Kerri FitzgeraldOncology | September 9, 2020
Researchers compared the efficacy of lenalidomide and dexamethasone paired with carfilzomib or bortezomib for the ...
Kerri FitzgeraldOncology | August 26, 2020
Maintenance therapy increases survival in patients with multiple myeloma (MM) compared with observation, according to a ...
Kerri FitzgeraldNon-Small Cell Lung Cancer | May 14, 2020
The U.S. Food and Drug Administration approved Retevmo® (selpercatinib) for three types of RET-mutated cancer: adults ...
Kerri FitzgeraldOncology | May 13, 2020
The U.S. Food and Drug Administration (FDA) approved Lynparza® (olaparib) in combination with Avastin® (bevacizumab) ...
Kerri FitzgeraldNon-Small Cell Lung Cancer | May 11, 2020
The U.S. Food and Drug Administration (FDA) approved Tabrecta™ (capmatinib) for adults with metastatic non-small cell ...
Kerri FitzgeraldNon-Small Cell Lung Cancer | April 15, 2020
Frontline tislelizumab plus chemotherapy significantly improved progression-free survival (primary endpoint) compared ...
Kerri FitzgeraldColorectal Cancer | April 14, 2020
The U.S. Food and Drug Administration (FDA) approved Braftovi® (encorafenib) in combination with cetuximab for ...